News

Neuropore Therapies Awarded Second Grant on its TLR2 Program from The Michael J. Fox Foundation for Parkinson’s Research January 4, 2018

Neuropore Therapies, Inc. has received a second grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) in support of its Toll-Like Receptor 2 (TLR2) antagonist program focused on modulating neuroinflammation and autophagy in Parkinson’s disease and other neurodegenerative diseases.

Neuropore Therapies Awarded Grant from The Michael J. Fox Foundation for Parkinson’s Research January 30, 2017

Neuropore Therapies, Inc. has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) in support of its Toll-Like Receptor 2 (TLR2) antagonist program focused on modulating neuroinflammation and autophagy in Parkinson’s disease and other neurodegenerative diseases.

Neuropore Therapies Announces Appointment of Dr. Errol De Souza as President and Chief Executive Officer January 23, 2017

Neuropore Therapies, Inc. announced today that Errol De Souza, Ph.D. has been appointed President and Chief Executive Officer effective immediately.

Neuropore Therapies (NPT) Announces Achievement of Key Program Milestone September 13, 2016

Based on promising findings from ongoing clinical and non-clinical studies, UCB awarded NPT a major program milestone of $5 million.

Neuropore publishes paper describing use of retinal imaging for evaluating potential therapies for Parkinson’s disease and other synucleinopathies August 4, 2016

The report in Scientific Reports describes findings that support the use of non-invasive retinal imaging in animal models as a tool to monitor the fate of α-synuclein accumulation in the CNS and to evaluate the effects of putative therapeutic agents targeting α-synuclein for Parkinson’s disease and other synucleinopathies

Neuropore Announces Successful Completion of Phase l with its Lead Compound NPT200-11 March 7, 2016

NPT200-11 was well tolerated in 55 volunteers after oral administration

Neuropore Therapies Commences Phase 1 Clinical Trials August 12, 2015

Neuropore Therapies Inc. commences Phase 1 clinical trials with NPT200-11; a potential new disease modifying treatment for Parkinson's Disease

Neuropore And UCB Enter Into World-Wide Collaboration And Agreement January 15, 2015

Companies collaborate in the development of a small molecule disease modifying treatment option for people living with Parkinson's disease

Completion Of A Study On Retinal Pathology In An Animal Model Of Parkinson's Disease April 8, 2014

Neuropore Therapies Inc. and collaborators at the University of California, San Diego complete a study on the progression of Parkinson's disease in Laboratory Animals Using Phoenix Research Labs' Retinal Imaging Technology.

Advancement Of NPT200-11 Into Preclinical Development January 30, 2014

NeuroPore Therapies, a San Diego based biopharmaceutical company dedicated to the discovery and development of novel therapeutics for neurodegenerative disorders, with support from the Michael J. Fox foundation, has initiated preclinical development of its lead compound for the treatment of Parkinson’s disease.